Articles
5 June 2009
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
152
Views
169
Downloads
Authors
Altmetrics
Downloads
Citations
Supporting Agencies
How to Cite
Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.351